ATE369383T1 - Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor - Google Patents

Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor

Info

Publication number: ATE369383T1
Authority: AT; Austria
Prior art keywords: clmf; cells; proteins; relates; present
Prior art date: 1989-12-22

Application number

AT97104656T

Other languages

English (en)

Inventor

Richard Anthony Chizzonite

Maurice Kent Gately

Ulrich Andreas Gubler

Jeffrey David W Alton J Hulmes

Yu-Ching Eugene Pan

Frank John Podlanski

Alvin Seth Stern

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1990-12-09

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE369383(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-12-09 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE369383T1 publication Critical patent/ATE369383T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97104656T 1989-12-22 1990-12-09 Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor ATE369383T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US45570889A	1989-12-22	1989-12-22
US52093590A	1990-05-09	1990-05-09
US57228490A	1990-08-27	1990-08-27

Publications (1)

Publication Number	Publication Date
ATE369383T1 true ATE369383T1 (de)	2007-08-15

Family

ID=27412641

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT90123670T ATE163675T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor
AT97104682T ATE366311T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
AT97104656T ATE369383T1 (de)	1989-12-22	1990-12-09	Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
AT97104860T ATE368112T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT90123670T ATE163675T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor
AT97104682T ATE366311T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT97104860T ATE368112T1 (de)	1989-12-22	1990-12-09	Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür

Country Status (11)

Country	Link
EP (4)	EP0790309B1 (de)
JP (2)	JP3238418B2 (de)
AT (4)	ATE163675T1 (de)
AU (2)	AU6834990A (de)
BG (1)	BG60933B2 (de)
CA (3)	CA2032653C (de)
DE (4)	DE69034247T2 (de)
DK (4)	DK0790308T3 (de)
HU (1)	HU211879A9 (de)
IE (1)	IE904694A1 (de)
NZ (1)	NZ236545A (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5456924A (en) *	1988-12-23	1995-10-10	Immunotec Research Corporation Ltd.	Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en)	1988-11-10	1998-09-22	Trinchieri; Giorgio	Antibodies to natural killer stimulatory factor
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
EP0375045A1 (de) *	1988-12-22	1990-06-27	Duphar International Research B.V	Annelierte Indolderivate
US6683046B1 (en)	1989-12-22	2004-01-27	Hoffmann-La Roche Inc.	Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6706264B1 (en)	1994-03-14	2004-03-16	Genetics Institute, Llc	Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) *	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ES2297831T3 (es)	1994-05-09	2008-05-01	Oxford Biomedica (Uk) Limited	Vectores retroviricos que presentan una tasa de recombinacion reducida.
WO1996024369A1 (en) *	1995-02-06	1996-08-15	Genetics Institute, Inc.	Formulations for il-12
US5891680A (en) *	1995-02-08	1999-04-06	Whitehead Institute For Biomedical Research	Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) *	1995-03-22	1995-05-10	Lynxvale Ltd	Anti-tumour treatment
US5853714A (en) *	1995-03-27	1998-12-29	Genetics Institute, Inc.	Method for purification of IL-12
US5880146A (en) *	1995-06-07	1999-03-09	Fuji Immunopharmaceuticals Corporation	Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) *	1995-10-25	1998-12-29	The United States Of America, As Represented By The Department Of Health & Human Services	Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) *	1996-05-13	1996-07-17	Hoffmann La Roche	Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0850951A4 (de) *	1996-06-04	2001-04-11	Juridical Foundation	Cytokin-protein aus katzen
JP2001503258A (ja) *	1996-10-18	2001-03-13	バレンティス・インコーポレーテッド	遺伝子発現および搬送系および用途
WO1998017689A2 (en) *	1996-10-18	1998-04-30	Valentis Inc.	Il-12 gene expression and delivery systems and uses
US6054487A (en) *	1997-03-18	2000-04-25	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) *	1997-03-19	1998-09-24	F. Hoffmann-La Roche Ag	USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) *	1997-06-03	2002-08-28	Chemo Sero Therapeut Res Inst	新規なイヌサイトカインタンパク質
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
ES2221717T3 (es)	1997-12-08	2005-01-01	Emd Lexigen Research Center Corp.	Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US7026456B1 (en)	1998-01-23	2006-04-11	Hoffman-La Roche, Inc.	Antibodies against human IL-12
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es)	1999-08-09	2002-08-12	Lexigen Pharm Corp	Complejos multiples de citosina-anticuerpo.
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
AU2005202420B2 (en) *	1999-09-09	2008-08-07	Merck Sharp & Dohme Corp.	Mammalian cytokines; related reagents and methods
KR100894359B1 (ko) *	1999-09-09	2009-04-22	쉐링 코포레이션	포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
EP1905832A3 (de) *	1999-09-09	2009-09-09	Schering Corporation	Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen
EP1228214A2 (de)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Erythropoietinformen mit verbesserten eigenschaften
US7115712B1 (en)	1999-12-02	2006-10-03	Maxygen, Inc.	Cytokine polypeptides
CA2399832C (en)	2000-02-11	2011-09-20	Stephen D. Gillies	Enhancing the circulating half-life of antibody-based fusion proteins
BR0112111A (pt)	2000-06-29	2003-05-06	Merck Patent Gmbh	Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
AU2002248571B2 (en)	2001-03-07	2007-01-18	Merck Patent Gmbh	Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
US6969517B2 (en)	2001-05-03	2005-11-29	Emd Lexigen Research Center Corp.	Recombinant tumor specific antibody and use thereof
RU2312677C9 (ru)	2001-12-04	2008-03-27	Мерк Патент Гмбх	Иммуноцитокины с модулированной селективностью
DK1572748T3 (da)	2002-12-17	2010-08-23	Merck Patent Gmbh	Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
EA011859B9 (ru)	2004-01-05	2013-07-30	Емд Лексиген Ресерч Сентер Корп.	Соединения для адресной доставки препарата к ткани или органу-мишени
BRPI0515858A (pt)	2004-12-21	2008-08-12	Centocor Inc	anticorpos anti-il-12, epìtopos, composições, métodos e usos
BRPI0620648B1 (pt)	2005-12-30	2022-12-20	Merck Patent Gesellschaft Mit Beschrãnkter Haftung	Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
EP2215125A1 (de)	2007-11-27	2010-08-11	Ablynx N.V.	Verfahren zur gewinnung von polypeptidkonstrukten mit zwei oder mehreren einzeldomänenantikörpern
US7891807B2 (en) *	2009-06-11	2011-02-22	Ana Nichole Mansuy	Decorative eyeglass temples
JP7468992B2 (ja)	2016-03-29	2024-04-16	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
US10189151B2 (en)	2016-11-14	2019-01-29	Snap-On Incorporated	Compact head body hammer
TW201922780A (zh) *	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (de)	2018-05-18	2022-02-23	Janssen Biotech, Inc.	Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
AU2019346134C1 (en)	2018-09-24	2024-06-20	Janssen Biotech, Inc.	Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2020279987A1 (en)	2019-05-23	2021-11-18	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AU2021276930A1 (en)	2020-05-21	2023-02-02	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
JP2893653B2 (ja) *	1988-11-10	1999-05-24	ジェネティックス・インスティテュート・インコーポレイテッド	ナチュラルキラー細胞刺激因子

1990
- 1990-12-09 DE DE69034247T patent/DE69034247T2/de not_active Revoked
- 1990-12-09 EP EP97104860A patent/EP0790309B1/de not_active Revoked
- 1990-12-09 EP EP90123670A patent/EP0433827B1/de not_active Expired - Lifetime
- 1990-12-09 AT AT90123670T patent/ATE163675T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69034249T patent/DE69034249T2/de not_active Revoked
- 1990-12-09 DK DK97104682T patent/DK0790308T3/da active
- 1990-12-09 AT AT97104682T patent/ATE366311T1/de not_active IP Right Cessation
- 1990-12-09 DK DK97104860T patent/DK0790309T3/da active
- 1990-12-09 AT AT97104656T patent/ATE369383T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69034244T patent/DE69034244T2/de not_active Revoked
- 1990-12-09 AT AT97104860T patent/ATE368112T1/de not_active IP Right Cessation
- 1990-12-09 EP EP97104656A patent/EP0790255B1/de not_active Revoked
- 1990-12-09 DK DK90123670T patent/DK0433827T3/da active
- 1990-12-09 DE DE69032086T patent/DE69032086T2/de not_active Expired - Lifetime
- 1990-12-09 EP EP97104682A patent/EP0790308B1/de not_active Revoked
- 1990-12-09 DK DK97104656T patent/DK0790255T3/da active
- 1990-12-19 CA CA002032653A patent/CA2032653C/en not_active Expired - Lifetime
- 1990-12-19 CA CA002346997A patent/CA2346997C/en not_active Expired - Lifetime
- 1990-12-19 CA CA002572802A patent/CA2572802A1/en not_active Abandoned
- 1990-12-19 NZ NZ236545A patent/NZ236545A/xx unknown
- 1990-12-20 AU AU68349/90A patent/AU6834990A/en not_active Abandoned
- 1990-12-21 IE IE469490A patent/IE904694A1/en not_active IP Right Cessation
- 1990-12-22 JP JP41325990A patent/JP3238418B2/ja not_active Expired - Lifetime
1994
- 1994-01-25 AU AU54712/94A patent/AU674363B2/en not_active Expired
- 1994-03-01 BG BG098632A patent/BG60933B2/bg unknown
1995
- 1995-06-20 HU HU95P/P00267P patent/HU211879A9/hu unknown
2001
- 2001-08-14 JP JP2001246031A patent/JP3375949B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69034244D1 (de)	2007-08-16
AU6834990A (en)	1991-06-27
CA2032653C (en)	2002-05-28
EP0790309B1 (de)	2007-07-25
DK0790308T3 (da)	2007-10-08
DE69034244T2 (de)	2008-04-03
CA2032653A1 (en)	1991-06-23
EP0790255A2 (de)	1997-08-20
AU5471294A (en)	1994-06-09
DE69032086D1 (de)	1998-04-09
EP0790255A3 (de)	2000-03-01
ATE163675T1 (de)	1998-03-15
BG60933B2 (bg)	1996-06-28
JP3238418B2 (ja)	2001-12-17
AU674363B2 (en)	1996-12-19
ATE368112T1 (de)	2007-08-15
DE69032086T2 (de)	1998-09-17
DK0790255T3 (da)	2007-11-26
DK0433827T3 (da)	1998-09-28
NZ236545A (en)	1993-04-28
DK0790309T3 (da)	2007-11-05
DE69034247T2 (de)	2008-04-17
DE69034249D1 (de)	2007-09-20
JPH05294999A (ja)	1993-11-09
EP0790308B1 (de)	2007-07-04
JP3375949B2 (ja)	2003-02-10
DE69034247D1 (de)	2007-09-06
EP0790309A1 (de)	1997-08-20
CA2346997A1 (en)	1991-06-23
CA2572802A1 (en)	1991-06-23
CA2346997C (en)	2007-02-20
EP0790308A1 (de)	1997-08-20
DE69034249T2 (de)	2008-05-29
ATE366311T1 (de)	2007-07-15
IE904694A1 (en)	1991-07-17
HU211879A9 (en)	1995-12-28
JP2002167400A (ja)	2002-06-11
IE990006A1 (en)	2000-11-01
IE990005A1 (en)	2000-11-01
EP0433827B1 (de)	1998-03-04
EP0433827A3 (en)	1992-07-01
IE990007A1 (en)	2000-11-01
EP0433827A2 (de)	1991-06-26
EP0790255B1 (de)	2007-08-08

Publication	Publication Date	Title
DE69034249D1 (de)	2007-09-20	Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
DE69332413D1 (de)	2002-11-21	Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie
ATE105869T1 (de)	1994-06-15	Formen des koloniestimulierungsfaktors 1.
DK0733067T3 (da)	1999-11-01	N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
MY102806A (en)	1992-11-30	Human interleukin-3 and muteins thereof
ATE167519T1 (de)	1998-07-15	T-zellen-wachstumsfaktor
DE69007744D1 (de)	1994-05-05	Verwendung von Interleukin 2 zur Behandlung von Leukämien.
ZA924674B (en)	1993-04-28	Cysteine depleted il-6 mutein
Nishihara et al.	1988	Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
EP0248583A3 (en)	1989-10-18	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ottmann et al.	1987	Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rG-CSF) on highly enriched hematopoietic progenitor cells
Schrader et al.	1982	Molecular classification of T-cell-derived lymphokines
BG60657B2 (en)	1995-11-30	Human recombinant interleukin-2 muteins
ES8703928A1 (es)	1987-03-01	Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante

Legal Events

Date	Code	Title	Description
2010-12-15	RZN	Patent revoked